IGC Pharma, Inc. (IGC) stock intrinsic value fair value estimate & owner earnings analysis

IGC Pharma is a small drug developer focused on Alzheimer's disease that is still in clinical trials. Its lead candidate, IGC-AD1, acts on the brain's CB1 receptor. It is in a Phase 2 trial called CALMA for agitation in Alzheimer's dementia. The trial runs at several centres, and patients are randomly assigned to the drug or a placebo without knowing which. The company reports interim results showing less agitation within two to six weeks than on placebo, and fewer sleep disturbances. During the year to March 2025 it added 13 research sites, including Miami Jewish Health and Butler Hospital. It also has earlier-stage candidates such as TGR-63 and is exploring AI models to spot early signs of Alzheimer's. Alongside the research it runs a small products business. Revenue in the year to March 2025 was $1.27 million: $1.16 million from white-label services, where it packages products under customers' brands, and $0.11 million from wellness products. 99.8% of it came from the United States. The company has moved its year-end from March to December and filed a transition report covering April to December 2025. How we measured it. We look at the cash the business produces for its owners. We start with operating cash flow and remove short-term swings in working capital. We then subtract stock-based pay, which we treat as a real cost (recently $1.6 to $2.8 million a year), and spending on equipment and patents. On this basis the business has lost money in each of the last ten fiscal years. In the five years to March 2025 the yearly shortfall ranged from $6.8 million to $13.0 million, with a middle value of about $9.8 million. That is roughly 9.5 cents for each of the 102.4 million shares outstanding at June 30, 2026. The best year was the latest full one, to March 2025, when the shortfall narrowed 23% to $6.8 million after the company narrowed its focus to life sciences. That improvement did not last. In the nine months to December 2025 the shortfall was $7.7 million, 33% worse than the same nine months a year earlier. In the six months to June 2026 it was $5.4 million. Both periods point to a yearly pace of about $10.3 to $10.7 million as research spending rose. So we start from $9.8 million a year, not from the one better year. One accounting item: about $3.2 million of non-cash other income made the reported net loss for the nine months to December 2025 look smaller. It coincided with a jump in the company's intangible assets. Because we count only cash it does not affect our figures, but the filings available to us did not let us confirm what it was. What the cases assume. None of the value rests on IGC-AD1 being approved or licensed, because no approval, licence or partnership exists today. Interim Phase 2 data are encouraging, but they are not a source of cash we can point to. The one approved treatment for this condition that the company names is brexpiprazole. It was approved in May 2023 after a much larger Phase 3 trial, which shows how much work would still lie ahead. So each case asks how long, and how fast, the company keeps spending before its programme either finds outside funding or stops. Base case (negative 33 cents per share): losses continue at about $9.8 million a year for four years. In that time CALMA finishes and the company begins the further studies it says it plans, testing IGC-AD1 as a treatment that slows the disease. Then the spending ends with nothing that can be shown to replace it. Discounted at 6%, that is about $34 million of losses for today's shareholders to fund, mostly through more share sales. Bear case (negative 57 cents per share): spending runs at the recent pace of about $10.5 million a year for seven years as a larger trial follows Phase 2. That fits a decade of unbroken losses and an accumulated deficit of about $130 million. Borrowing adds risk: loans of about $1.1 million were on the books by June 2026, against almost none six months earlier. Bull case (negative 12 cents per share): management repeats the discipline of the year to March 2025, holds losses to $6.8 million a year, and the programme reaches a conclusion within two years. What the shares appear to be worth. In all three cases the company appears to be worth less than nothing to today's owners. In the base case the gap is roughly $34 million, or 33 cents a share. Debt is not the cause: total liabilities were only about $3.4 million at June 30, 2026. The cause is that the losses shareholders are expected to fund exceed anything the business can yet be shown to return. We gave no separate value to the patents, the land held for sale or the small white-label business. Funding is the pressing issue. Cash was $331,000 at June 30, 2026, while operations used $2.6 million of cash in the first half of 2026 and unpaid supplier bills grew. The company has relied on share sales, including a $60 million programme of selling shares gradually through A.G.P./Alliance Global Partners. It also has a $12 million credit facility from O-Bank of Taiwan. In its March 2025 annual report, management judged these resources enough for the following twelve months. Every new share sale spreads future results over more shares: shares outstanding rose from 66.7 million in March 2024 to 102.4 million in June 2026. What would make this wrong. Real, provable value would come from a completed, positive Phase 2 result followed by a signed licensing or partnership deal that pays the company cash, or from an approval. None of the cases include that. Until something like it exists, we see no price at which the shares offer a margin of safety.